Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(4.09)
# 503
Out of 5,140 analysts
506
Total ratings
46.84%
Success rate
14.76%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Reiterates: Buy | $20 | $4.90 | +308.16% | 29 | Jan 9, 2026 | |
| PCRX Pacira BioSciences | Reiterates: Buy | $38 | $20.24 | +87.75% | 4 | Jan 9, 2026 | |
| OTLK Outlook Therapeutics | Maintains: Neutral | $1 → $0.5 | $0.51 | -1.19% | 19 | Jan 2, 2026 | |
| BHVN Biohaven | Reiterates: Neutral | $11 | $12.87 | -14.53% | 17 | Dec 26, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $23 → $26 | $22.98 | +13.14% | 22 | Dec 12, 2025 | |
| RZLT Rezolute | Maintains: Buy | $14 → $5 | $3.02 | +65.56% | 19 | Dec 12, 2025 | |
| RAPP Rapport Therapeutics | Maintains: Buy | $34 → $40 | $26.40 | +51.52% | 3 | Dec 9, 2025 | |
| PRAX Praxis Precision Medicines | Reiterates: Buy | $340 | $312.60 | +8.77% | 30 | Dec 8, 2025 | |
| DARE Daré Bioscience | Reiterates: Buy | $12 | $1.94 | +518.56% | 18 | Dec 2, 2025 | |
| TBPH Theravance Biopharma | Maintains: Buy | $15 → $20 | $20.37 | -1.82% | 16 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $4 | $4.19 | -4.53% | 15 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $57 → $45 | $20.95 | +114.80% | 27 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $774 → $915 | $816.37 | +12.08% | 41 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $2.34 | +583.76% | 27 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $83.89 | -4.64% | 35 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $46 | $33.85 | +35.89% | 25 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $35 | $26.02 | +34.51% | 23 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $3.50 | +100.00% | 10 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $118 | $74.89 | +57.56% | 16 | Jul 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $81 | $55.41 | +46.18% | 24 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $53 | $41.00 | +29.27% | 5 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.64 | +326.83% | 25 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $34 | $32.29 | +5.30% | 16 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $26.70 | -28.84% | 4 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $1.95 | +823.08% | 7 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $1.36 | +26,370.59% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $2.49 | +301.61% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $184.87 | -1.55% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $8.87 | +111.39% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $41.95 | -57.09% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $31.41 | -74.53% | 7 | Jun 11, 2019 |
Evolus
Jan 9, 2026
Reiterates: Buy
Price Target: $20
Current: $4.90
Upside: +308.16%
Pacira BioSciences
Jan 9, 2026
Reiterates: Buy
Price Target: $38
Current: $20.24
Upside: +87.75%
Outlook Therapeutics
Jan 2, 2026
Maintains: Neutral
Price Target: $1 → $0.5
Current: $0.51
Upside: -1.19%
Biohaven
Dec 26, 2025
Reiterates: Neutral
Price Target: $11
Current: $12.87
Upside: -14.53%
Roivant Sciences
Dec 12, 2025
Maintains: Buy
Price Target: $23 → $26
Current: $22.98
Upside: +13.14%
Rezolute
Dec 12, 2025
Maintains: Buy
Price Target: $14 → $5
Current: $3.02
Upside: +65.56%
Rapport Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $34 → $40
Current: $26.40
Upside: +51.52%
Praxis Precision Medicines
Dec 8, 2025
Reiterates: Buy
Price Target: $340
Current: $312.60
Upside: +8.77%
Daré Bioscience
Dec 2, 2025
Reiterates: Buy
Price Target: $12
Current: $1.94
Upside: +518.56%
Theravance Biopharma
Nov 11, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $20.37
Upside: -1.82%
Nov 6, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $4.19
Upside: -4.53%
Oct 31, 2025
Maintains: Buy
Price Target: $57 → $45
Current: $20.95
Upside: +114.80%
Oct 31, 2025
Maintains: Buy
Price Target: $774 → $915
Current: $816.37
Upside: +12.08%
Oct 10, 2025
Reiterates: Buy
Price Target: $16
Current: $2.34
Upside: +583.76%
Oct 8, 2025
Reiterates: Buy
Price Target: $80
Current: $83.89
Upside: -4.64%
Sep 9, 2025
Reiterates: Neutral
Price Target: $46
Current: $33.85
Upside: +35.89%
Sep 4, 2025
Reiterates: Buy
Price Target: $35
Current: $26.02
Upside: +34.51%
Aug 14, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $3.50
Upside: +100.00%
Jul 3, 2025
Reiterates: Buy
Price Target: $118
Current: $74.89
Upside: +57.56%
Jun 27, 2025
Reiterates: Buy
Price Target: $81
Current: $55.41
Upside: +46.18%
May 13, 2025
Reiterates: Buy
Price Target: $53
Current: $41.00
Upside: +29.27%
Apr 29, 2025
Reiterates: Buy
Price Target: $7
Current: $1.64
Upside: +326.83%
Apr 23, 2025
Reiterates: Buy
Price Target: $34
Current: $32.29
Upside: +5.30%
Apr 3, 2025
Reiterates: Buy
Price Target: $19
Current: $26.70
Upside: -28.84%
Mar 7, 2025
Reiterates: Buy
Price Target: $18
Current: $1.95
Upside: +823.08%
Oct 1, 2024
Reiterates: Buy
Price Target: $360
Current: $1.36
Upside: +26,370.59%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $2.49
Upside: +301.61%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $184.87
Upside: -1.55%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $8.87
Upside: +111.39%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $41.95
Upside: -57.09%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $31.41
Upside: -74.53%